[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359160-105":59,"doc-detail-359160-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","clinical-practice-guideline-for-high-risk-human-papillomavirus-testing-in-cervical-cancer-screening-a-consensus-statement-from-the-korean-society-of-gynecologic-oncology","Clinical practice guideline for high-risk human papillomavirus testing in cervical cancer screening - a consensus statement from the Korean Society of Gynecologic Oncology","","High-risk human papillomavirus (hrHPV) is a necessary cause of cervical cancer, and hrHPV testing has become an effective screening option that addresses limitations of cytology-based screening. This consensus-based clinical practice guideline was developed by the Korean Society of Gynecologic Oncology using systematic review of domestic and international evidence and input from multidisciplinary public hearings. Expert consensus produced four key recommendations on eligibility age, testing interval, assay requirements for HPV genotypes 16/18 and other high-risk types, and standardized testing conditions with rigorous internal and external quality control to support consistent implementation in Korea.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-practice-guideline-for-high-risk-human-papillomavirus-testing-in-cervical-cancer-screening-a-consensus-statement-from-the-korean-society-of-gynecologic-oncology/359160/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-practice-guideline-for-high-risk-human-papillomavirus-testing-in-cervical-cancer-screening-a-consensus-statement-from-the-korean-society-of-gynecologic-oncology/359160.png","ImageObject",300,407,{"name":92,"@type":93},"Margaret","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the purpose of this consensus clinical practice guideline?","Question",{"text":113,"@type":114},"It provides standardized recommendations to support consistent and rational implementation of hrHPV testing in cervical cancer screening in Korea.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"For whom may hrHPV testing be considered, and what screening interval is recommended?",{"text":118,"@type":114},"HrHPV testing may be considered for women aged 25 years or older, with a recommended screening interval of 3 to less than 5 years.",{"name":120,"@type":111,"acceptedAnswer":121},"What assay and reporting requirements are emphasized for hrHPV testing?",{"text":122,"@type":114},"Screening assays should differentiate HPV genotypes 16 and 18 and detect other high-risk types, and testing should be done with standardized specimen handling and documentation of HPV 16/18 status in positive cases.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},359160,1790153226,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","J Gynecol Oncol. 2026 Mar;37(2):e90 [https://doi.org/10.3802/jgo.2026.37.e90](https://doi.org/10.3802/jgo.2026.37.e90)[ ](https://doi.org/10.3802/jgo.2026.37.e90)pISSN 2005-0380·eISSN 2005-0399  \nMeeting Report  \nReceived: Jan 29, 2026  \nAccepted: Jan 31, 2026  \nPublished online: Mar 1, 2026  \nCorrespondence to  \nShin-Wha Lee  \nDepartment of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea.  \nEmail: [swhlee@amc.seoul.kr](swhlee@amc.seoul.kr)  \nJaeman Bae  \nDepartment of Obstetrics and Gynecology, Hanyang University Medical Center, 222-1 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea.  \n[Email: obgybae@hanyang.ac.kr](Email: obgybae@hanyang.ac.kr)  \n© 2026. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nORCID iDs  \nJu-Hyun Kim  [https://orcid.org/0000-0003-4007-5739](https://orcid.org/0000-0003-4007-5739)[ ](https://orcid.org/0000-0003-4007-5739)[Seung-Hyuk Shim](Seung-Hyuk Shim)  [https://orcid.org/0000-0001-8043-2257](https://orcid.org/0000-0001-8043-2257)[ ](https://orcid.org/0000-0001-8043-2257)[Kyung-Jin Min](Kyung-Jin Min)  [https://orcid.org/0000-0002-5783-4968](https://orcid.org/0000-0002-5783-4968)  \nClinical practice guideline for high-risk human papillomavirus testing in cervical cancer screening: a consensus statement from the Korean Society of Gynecologic Oncology  \nJu-Hyun Kim ,1 Seung-Hyuk Shim ,2 Kyung-Jin Min ,3 Jae-Kwan Lee ,4 Chong Woo Yoo ,5 Min-Jung Kwon ,6 Shin-Wha Lee ,1 Jaeman Bae  7  \n1Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea  \n2Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea  \n3Department of Obstetrics and Gynecology, Korea University Ansan Hospital, Ansan, Korea 4Department of Obstetrics and Gynecology, Korea University Guro Hospital, Seoul, Korea  \n5Department of Pathology, National Cancer Center, Goyang, Korea  \n6Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea  \n7Department of Obstetrics and Gynecology, Hanyang University Medical Center, Seoul, Korea  \nABSTRACT  \nHigh-risk human papillomavirus (hrHPV) is a necessary cause of cervical cancer, and hrHPV testing has increasingly been recognized as an effective screening tool that overcomes the limitations of cytology-based screening. However, standardized clinical guidance for the use of hrHPV testing in cervical cancer screening has been limited in Korea, resulting in variability in clinical practice. This consensus-based clinical practice guideline was developed under the auspices of the Korean Society of Gynecologic Oncology through multidisciplinary collaboration involving experts in gynecology, pathology, laboratory medicine, and public health. Relevant domestic and international evidence was systematically reviewed, and input from diverse clinical settings was incorporated through four public hearings. Final recommendations were established through expert consensus. The guideline presents four key recommendations: hrHPV testing may be considered for women aged 25 years or older, with a recommended screening interval of 3 to \u003C5 years; screening assays should differentiate HPV genotypes 16 and 18 and detect other high-risk types, with preference given to clinically validated tests; testing should be performed in appropriately equipped settings with standardized specimen handling and reportin","cbCaiurhEGi39N5I","https://ap.wps.com/l/cbCaiurhEGi39N5I","pdf",8718964,11,"English","# Abstract\n# Keywords\n# Meeting report\n# Correspondence and authors\n# Funding and conflict of interest\n# Data availability\n# Author contributions","[{\"question\":\"What is the purpose of this consensus clinical practice guideline?\",\"answer\":\"It provides standardized recommendations to support consistent and rational implementation of hrHPV testing in cervical cancer screening in Korea.\"},{\"question\":\"For whom may hrHPV testing be considered, and what screening interval is recommended?\",\"answer\":\"HrHPV testing may be considered for women aged 25 years or older, with a recommended screening interval of 3 to less than 5 years.\"},{\"question\":\"What assay and reporting requirements are emphasized for hrHPV testing?\",\"answer\":\"Screening assays should differentiate HPV genotypes 16 and 18 and detect other high-risk types, and testing should be done with standardized specimen handling and documentation of HPV 16/18 status in positive cases.\"}]","Clinical practice guideline for high-risk human papillomavirus testing in cervical cancer screening - a consensus statement from the Korean Society of Gynecologic Oncology | PDF",1790136296,28]